Collegium Pharmaceutical (NASDAQ:COLL) Announces Earnings Results, Beats Estimates By $0.22 EPS

Collegium Pharmaceutical (NASDAQ:COLL) posted its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.22, Briefing.com reports. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. During the same period in the previous year, the firm posted $1.13 EPS. Collegium Pharmaceutical’s revenue was up 7.2% compared to the same quarter last year. Collegium Pharmaceutical updated its FY 2024 guidance to EPS.

Collegium Pharmaceutical Trading Up 0.5 %

NASDAQ:COLL traded up $0.18 on Friday, reaching $35.50. 413,104 shares of the company’s stock were exchanged, compared to its average volume of 471,066. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 14.79 and a beta of 0.93. Collegium Pharmaceutical has a 52-week low of $20.95 and a 52-week high of $40.95. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. The business has a fifty day moving average of $33.09 and a 200-day moving average of $34.84.

Analyst Upgrades and Downgrades

COLL has been the topic of several research reports. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. HC Wainwright raised shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a research note on Tuesday, July 30th. Piper Sandler restated a “neutral” rating and issued a $37.00 price target (down from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Insider Activity

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the transaction, the executive vice president now owns 105,902 shares of the company’s stock, valued at approximately $3,598,549.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $33.98, for a total value of $1,930,301.86. Following the sale, the executive vice president now owns 105,902 shares of the company’s stock, valued at approximately $3,598,549.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the transaction, the director now directly owns 44,775 shares of the company’s stock, valued at $1,446,232.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 105,502 shares of company stock valued at $3,540,796. 3.98% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.